FDA revokes emergency use of Hydroxychloroquine for treating Covid-19 patients

In the United States, the Food and Drug Administration (FDA) has revoked its emergency use authorization for the drugs Hydroxychloroquine and Chloroquine for the treatment of COVID-19 patients after concluding that they may not be effective to cure the virus infections.

The Food and Drug Administration (FDA) has said its decision is based on new information, including clinical trial data results, that have led it to conclude that the drugs may not be effective to treat COVID-19 and that its potential benefits for such use



do not outweigh its known and potential risks.

FDA Chief Scientist Denise Hinton, in a letter dated 15th of June to Gary Disbrow of Biomedical Advanced Research and Development Authority (BARDA), said as of the date, the oral formulations of Hydroxychloroquine (HCQ) and Chloroquine (CQ) are no longer authorized by the FDA to treat COVID-19. She said that the FDA now believes that the suggested dosing regimens for CQ and HCQ are unlikely to produce an antiviral effect.